The Scientist

» monoclonal antibodies

Most Recent

image: Antibody Treatment Lessens Zika’s Effects in Mice

Antibody Treatment Lessens Zika’s Effects in Mice

By | November 7, 2016

When given to pregnant rodents, a human antibody against a viral envelope protein reduces fetal infection, scientists show.

0 Comments

image: Cautious Optimism About ZMapp Trial

Cautious Optimism About ZMapp Trial

By | February 25, 2016

The Ebola drug increased survival in a small study, but the effect was not statistically significant.

0 Comments

image: Single Antibody Protects Macaques from Ebola

Single Antibody Protects Macaques from Ebola

By | February 25, 2016

The “just right” binding properties of a monoclonal antibody from an Ebolavirus survivor help it neutralize the virus.

0 Comments

image: In Situ Antibodies

In Situ Antibodies

By | February 2, 2016

Compared with systemic injections, localized antibody therapies may be more effective for some indications.

2 Comments

image: Antibody Alternatives

Antibody Alternatives

By and | February 1, 2016

Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

2 Comments

image: Exercises for Your Abs

Exercises for Your Abs

By | February 1, 2016

Companies make the antibodies, but it’s up to you to make sure they work in your experiments.

3 Comments

image: Building Better Reagents

Building Better Reagents

By and | February 1, 2016

Facing problems of inconsistent, time-consuming, and costly antibody production, some researchers are turning to alternatives to target specific proteins of interest, in the lab and in the clinic.

0 Comments

Some antibodies designed to eliminate the plaques prominent in Alzheimer’s disease can aggravate neuronal hyperactivity in mice.

1 Comment

image: Two-Faced Proteins May Tackle HIV Reservoirs

Two-Faced Proteins May Tackle HIV Reservoirs

By | October 21, 2015

Researchers design antibody-like proteins to awaken and destroy HIV holdouts.

0 Comments

image: Novartis Buys Rights to GSK MS Drug for $1 Billion

Novartis Buys Rights to GSK MS Drug for $1 Billion

By | August 24, 2015

The multiple sclerosis treatment has yet to be tested in Phase 3 clinical trials.

0 Comments

Popular Now

  1. Unstructured Proteins Help Tardigrades Survive Desiccation
  2. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  3. Opinion: On “The Impact Factor Fallacy”
  4. Inflammation Drives Gut Bacteria Evolution
Business Birmingham